Abstracts tagged "Osteoarthritis"

Abstract Number: 0919 • ACR Convergence 2025
Proteomic Profiling of Extracellular Vesicles from Synovial Fluid of RA and OA Patients Reveals Cell-type-specific subpopulations and Disease Related Patterns
Stefanie Kurth¹, Andre Tiaden¹, Edveena Hanser¹, Simone Häner¹, Stavros Giaglis¹, Florian Geier¹, Dominik Burri¹, Katarzyna Buczak¹, Ute Heider², Stefan Wild², Yves Acklin¹, Christian Egloff¹ and Diego Kyburz³, ¹University of Basel, Basel, Switzerland, ²Miltenyi Biotec, Bergisch-Gladbach, Germany, ³University Hospital Basel, Basel, Switzerland
Background/Purpose: Extracellular vesicles (EVs) are secreted by virtually all cells and are known to carry bioactive cargo including proteins, RNA, DNA and metabolites. Analysis of…
Abstract Number: 0331 • ACR Convergence 2025
Safety and Efficacy of Colchicine in Osteoarthritis: A Systematic Review and Meta-Analysis of 6,965 Patients
Mohamed Abdelsalam¹, Bassant Elaraby Elsayed Badwy², Menat Alla Ayman Ali Mahdy², Maryam Lasheen³, Hadeer Hafez⁴, Omar Sameh Nabil El Sedafy¹ and Mohamed Reda Awad⁵, ¹Misr University For Science and Technology, ⁶ october, Al Jizah, Egypt, ²Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, ³Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, ⁴⁶th October University, ⁶ october, Al Jizah, Egypt, ⁵Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt

Background/Purpose: Osteoarthritis (OA) is the most common joint disease, that leads to significant pain and affects quality of life, particularly in older adults. Current treatments…
Abstract Number: 0316 • ACR Convergence 2025
Increased Synovial Inflammation, Xist Escape Gene Expression and Knee Pain in Females with Osteoarthritis
Bella Mehta¹, Miguel Otero², Michael Mazzucco³, Jenelys Ruiz-Ortega⁴, Caryn Hale⁴, Fuadur Omi⁴, Syed Henah Balkhi⁵, Purva Singh³, Samantha Lessard³, Wei Wang⁴, Maryam Aslam⁴, Tristan Maerz⁶, Peter Sculco³, Anne-Marie Malfait⁷, Xiaoshun Li⁸, Yiyuan Wu⁹, Shady Younis¹⁰, William Robinson¹¹, Daniel Ramirez¹², Edward DiCarlo¹² and Dana Orange⁵, ¹Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ, ²Hospital For Special Surgery, New York, ³Hospital For Special Surgery, New York, NY, ⁴The Rockefeller University, New York, ⁵The Rockefeller University, New York, NY, ⁶University of Michigan, Ann Arbor, MI, ⁷Rush University Medical Center, Chicago, ⁸Hospital For Special Surgery, Ridgewood, NY, ⁹Weill Cornell Medicine, New York, NY, ¹⁰Stanford University, Stanford, CA, ¹¹Stanford University, Palo Alto, CA, ¹²Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: MRI evidence of synovitis and bone marrow lesions, but not cartilage degeneration associate with pain in osteoarthritis (OA). In this work, we integrated clinical,…
Abstract Number: L04 • ACR Convergence 2024
Performance of an Artificial Intelligence Model Compared to Multiple Human Experts in Scoring Synovitis Severity and Osteophyte Severity on Joint Ultrasound Images
Anders Weber¹, Mads Ammitzbøll Danielsen², Bill Aplin Frederiksen³, Hilde Berner Hammer⁴, Benjamin Schultz Overgaard³, Lene Terslev², Thiusius Rajeeth Savarimuthu⁵ and Soren Andreas Just³, ¹ROPCA, Odense, Denmark, ²Center for Rheumatology and Spine Disease, Rigshospitalet, Glostrup, Denmark, ³Section of Rheumatology, Department of Medicine, Svendborg Sygehus OUH, Svendborg, Denmark, ⁴Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, Faculty of Medicine, University of Oslo, Oslo, Norway, ⁵Mærsk Mc-Kinney Møller Institute, University of Southern Denmark, Odense, Denmark
Background/Purpose: To evaluate the agreement of an artificial intelligence (AI) model designed to assess greyscale and Doppler synovitis severity and osteophyte severity in hand joints…
Abstract Number: L08 • ACR Convergence 2024
A Phase 2b, Randomized, Double-blind, Placebo-controlled, Dose-ranging and Parallel-group Study to Evaluate the Safety and Efficacy of XG005 in Subjects with Painful Osteoarthritis of the Knee
Limin Ren¹, Wenjie Zheng², Zhenpeng Guan³, Yang Zhang⁴, Zeyu Huang⁵, Tong Li⁶, Yuwei Peng⁷, Qiuli Wu⁸, Wei Gou⁹, Wei Zhao¹⁰, Pengyan Qiao¹¹, Xiaoli Pan¹² and Guang-Liang Jiang¹³, ¹Peking University, People’s Hospital, Rheumatology and Immunology Department, Beijing, China, ²Yantai Yuhuangding Hospital of Qingdao University, Department of Orthopedics, Yantai, China, ³Peking University, Shougang Hospital, Department of Orthopedics, Beijing, China, ⁴Division of Orthopaedic Surgery, Nanfang Hospital, Southern Medical University, Guangzhou, China, ⁵West China Hospital of Sichuan University, Department of Orthopedics, Chengdu, China, ⁶Xiangya Hospital of Central South University, Rheumatology and Immunology Department, Changsha, China, ⁷PingXiang People’s Hospital, Rheumatology and Immunology Department, Pingxiang, China, ⁸Tianjin Medical University General Hospital, Department of Orthopedics, Tianjin, China, ⁹Hebei Petrochina Central Hospital, Rheumatology and Immunology Department, Langfang, China, ¹⁰Central Hospital Affiliated to Shenyang Medical College, Department of Orthopedics, Shenyang, China, ¹¹Shanxi Bethune Hospital, Shanxi Academy of Medical Sciences, Third Hospital of Shanxi Medical University, Tongji Shanxi Hospital, Rheumatology and Immunology Department, Taiyuan, China, ¹²Affiliated Hospital of Zunyi Medical University, Rheumatology and Immunology Department, Zunyi, China, ¹³Xgene Pharmaceutical, Lexington, MA
Background/Purpose: Osteoarthritis (OA) affects 595 million people globally; cases are projected to increase 49-95% for various joints by 2050 as populations age (GBD 2023). OA…
Abstract Number: L15 • ACR Convergence 2024
LEVI-04, a Novel neurotrophin-3 Inhibitor, Substantially Improves Pain and Function Without Deleterious Effects on Joint Structure in People with Knee Osteoarthritis: A Randomized Controlled Phase II Trial
Philip Conaghan¹, Ali Guermazi², Nathaniel Katz³, Asger Bihlet⁴, Dror Rom⁵, Michael Perkins⁶, Bernadette Hughes⁶, Claire Herholdt⁶, Iwona Bombelka⁶ and Simon Westbrook⁶, ¹University of Leeds, Leeds, United Kingdom, ²Boston University, West Roxbury, MA, ³Rin Sof Innovation, Ltd, Boston, MA, ⁴NBCD A/S, Soeborg, Denmark, ⁵Prosoft Clinical, Chesterbrook, ⁶Levicept Ltd, Ramsgate, United Kingdom
Background/Purpose: There is an urgent need for new therapies to treat OA. Excess neurotrophins (NT) are implicated in OA and other painful conditions. Previous OA…
Abstract Number: 0023 • ACR Convergence 2024
Adenosine and Guanosine-based Oligonucleotide Attenuates Catabolic Phenotypes in Chondrocytes and Slows Progression of Surgically Induced Osteoarthritis
Yoonhee Kim¹, Jin Han² and Seungwoo Han³, ¹Kyungpook National University School of Medicine, Buk-gu, Daegu, Republic of Korea, ²Kyungpook National University, Buk-gu, Daegu, Republic of Korea, ³Kyungpook national university hospital, Daegu, South Korea
Background/Purpose: Adenosine is a potent endogenous modulator of inflammation; however, its clinical application is limited due to its extremely short half-life in blood. In this…
Abstract Number: 0790 • ACR Convergence 2024
CoLchicine for Treatment of OsteoArthritis of the Knee: Clinical Outcomes from a 90-day Double-Blind, Placebo-Controlled Study
Jonathan Samuels¹, Katherine Tse², Wei David², maryfe Coronel², Fernando Bomfim², Renata La Rocca Vieira³, Nicole Leung⁴, Svetlana Krasnokutsky Samuels⁵, Michael Toprover⁶ and Michael Pillinger⁷, ¹NYU Langone, Rye Brook, NY, ²NYU Langone Health, new york, NY, ³NYU., New York, NY, ⁴New York University Langone Medical Center, New York, NY, ⁵Summit Health, Rye Brook, NY, ⁶New York University Langone Health, New York, NY, ⁷New York University Grossman School of Medicine, New York,, NY
Background/Purpose: Knee osteoarthritis (OA) leads to progressive disability, but approved pharmacologic treatments target analgesia without affecting disease course. Colchicine is well-tolerated and inhibits inflammation thought…
Abstract Number: 1172 • ACR Convergence 2024
Participation in Baseball/Softball Associates with Increased Risk for Knee Pain and Osteoarthritis as an Adult: Data from the Osteoarthritis Initiative
Christopher Boldt¹, Jeffrey Driban², Timothy McAlindon², Andrea Kriska³, Bonny Rockette-Wagner³, Charles Eaton⁴, Marc Hochberg⁵, Kent Kwoh⁶, Michael Nevitt⁷ and Grace Lo⁸, ¹Baylor College of Medicine, Houston, TX, ²University of Massachusets, Worchester, MA, ³University of Pittsburgh, Pittsburgh, PA, ⁴Memorial Hospital of Rhode Island, Pawtucket, RI, ⁵University of Maryland School of Medicine, Cambridge, MD, ⁶University of Arizona, Tucson, AZ, ⁷University of California, San Francisco, San Francisco, CA, ⁸Baylor College of Medicine / MEDVAMC, Houston, TX
Background/Purpose: Baseball is often referred to as “America’s Pastime” and youth in the United States commonly participate in baseball and softball. With the increasing popularity…
Abstract Number: 1194 • ACR Convergence 2024
Treatment Effect of Lorecivivint Across Multiple Trials in Patients with Knee OA: A Meta-analysis
Christopher Swearingen¹, Jeyanesh Tambiah² and Yusuf Yazici³, ¹Biosplice Therapeutics, Inc, San Diego, CA, ²Biosplice Therapeutics Inc., San Diego, CA, ³NYU Grossman School of Medicine, La Jolla, CA
Background/Purpose: Lorecivivint (LOR), an intra-articular (IA) CLK/DYRK inhibitor thought to modulate inflammatory and Wnt pathways has previously appeared safe, improved patient-reported outcomes (PROs) compared with…
Abstract Number: 1210 • ACR Convergence 2024
Optimal Definitions of Worsening Cartilage Using Sequential MRI OsteoArthritis Knee Scores (MOAKS)
Kathryn Bacon¹, mike LaValley², Tuhina Neogi³, Ali Guermazi³, Frank Roemer³, Neil Segal⁴, Cora Lewis⁵, Michael Nevitt⁶, David Felson⁷ and John Lynch⁸, ¹Boston University, Webster, NH, ²Boston University School of Public Health, Arlington, MA, ³Boston University Chobanian & Avedisian School of Medicine, Boston, MA, ⁴University of Kansas, Kansas City, KS, ⁵University of Alabama at Birmingham, Birmingham, AL, ⁶University of California, San Francisco, San Francisco, CA, ⁷Boston University, Boston, MA, ⁸UCSF, San Francisco, CA
Background/Purpose: The MRI OsteoArthritis Knee Score (MOAKS) is increasingly used in studies of knee osteoarthritis. Our aim was to evaluate methods using MOAKS scores to…
Abstract Number: 1667 • ACR Convergence 2024
Correlates of Physical Activity (PA) in Persons Undergoing Total Knee Arthroplasty (TKA): Does Pain Matter?
Elena Losina¹, Jamie Collins¹, Clare Safran-Norton¹, Mike Paskewicz¹, Faith Selzer², Sonia Pavlesen³, Kelly Frier¹, Jon Dhani¹, Darya Lee¹, Ella Macdonald³, Alexa Streicher³, Linda Ehrlich-Jones⁴, Neil Segal⁵, Christine Pellegrini⁶, Elizabeth Wellsandt⁷, Rowland Chang⁸ and Jeffrey Katz¹, and KArAT Team, ¹Brigham and Women's Hospital, Boston, MA, ²Brigham and Women's Hospital, Amesbury, MA, ³University of Buffalo, Buffalo, NY, ⁴Shirley Ryan Ability Lab, Chicago, IL, ⁵University of Kansas, Kansas City, KS, ⁶University of South Carolina, Columbia, SC, ⁷University of Nebraska Medical Center, Omaha, NE, ⁸Northwestern University Division of Rheumatology, Chicago, IL
Background/Purpose: Low PA in persons with symptomatic knee osteoarthritis (OA) has often been attributed to pain. Evolving data suggest that TKA recipients do not increase…
Abstract Number: 2090 • ACR Convergence 2024
Prevalence of Steatotic Liver Disease and Liver Fibrosis Among Patients with Osteoarthritis (OA)
Athanasios Vassilopoulos¹, Stephanos Vassilopoulos², Markos Kalligeros², Eleftherios Mylonakis³ and Anthony M. Reginato⁴, ¹Warren Alpert Medical School of Brown University, Providence, RI, ²Division of Internal Medicine, Warren Alpert Medical School of Brown University, Rhode Island Hospital, Providence, Rhode Island, Providence, RI, ³Department of Medicine, Houston Methodist Hospital, Houston, ⁴Brown University, Providence, RI
Background/Purpose: Steatotic liver disease (SLD) and osteoarthritis (OA) affect a large proportion of the general population and prevalence of both is expected to increase given…
Abstract Number: 2106 • ACR Convergence 2024
EP-104IAR (Long-Acting Intra-Articular Injection of Fluticasone Propionate) Shows Sustained Improvement in Pain for Subjects with Moderate Baseline Pain and BMI Less Than 30 in SPRINGBOARD, a Phase 2, Randomized, 24-Week Study of Osteoarthritis of the Knee
Amanda Malone¹, James Helliwell¹, Mark Kowalski¹, Helene Rovsing², Sidsel Lynggaard Boll³, Asger Reinstrup Bihlet⁴, Claire Prener Miller⁵, Alejandro Castillo Mondragón⁶, Yanqi Li⁶, Christine Dobek¹, Vik Peck¹, Andrew Dye¹, Mike Wilmink⁷, Lee Simon⁸ and Philip G Conaghan⁹, ¹Eupraxia Pharmaceuticals, Victoria, BC, Canada, ²NBCD A/S, Nordjylland, Denmark, ³NBCD A/S, Syddanmark, Denmark, ⁴NBCD A/S, Soeborg, Denmark, ⁵Novo Nordisk A/S, Bagsværd, Denmark, ⁶NBCD A/S, Soborg, Denmark, ⁷OrthoArizona, Phoenix, AZ, ⁸SDG LLC, West Newton, MA, ⁹Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Knee osteoarthritis (KOA) is a leading cause of disability associated with risk of cardiovascular disease and reduced self-management of diabetes and hypertension. Recommended treatment…
Abstract Number: 0024 • ACR Convergence 2024
Trans-Signaling by Soluble CD14 Sensitizes Chondrocytes to Lipopolysaccharide Stimuli, Increasing Chondrocyte Inflammatory Responses
Anna E. Rapp, Baofeng Hu and Carla Scanzello, University of Pennsylvania, Philadelphia, PA
Background/Purpose: The understanding of osteoarthritis (OA) has evolved significantly over the past decade. Recently attention is being drawn to the role of pattern-recognition receptor (PRR)…

« Previous Page
1
…
7
8
9
10
11
…
71
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].